Trial Profile
A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs AFP 464 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Apr 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Nov 2012 Planned number of patients changed from 75 to 60 as reported by ClinicalTrials.gov.